Acorn Biolabs Explores AI-Guided Regenerative Medicine
publishers 113articles 375first reported 23 Sep, 14:00 UTCdeveloping since 30 Sep · 33 editions
Acorn Biolabs founder Drew Taylor says artificial intelligence could support regenerative medicine by predicting how a stem cell will perform from a single image and helping develop treatment plans tailored to an individual’s biology.
In an interview with Fast Company, Taylor discussed the company’s goal of using AI in efforts to counter aspects of biological aging. He also addressed broader questions associated with longer lifespans, including whether social systems and personal retirement savings are prepared for people to live longer.
HOW THIS STORY WAS MADE
Written from 8 articles, 7 with the publisher's own text; 8 independent newsrooms once syndicated copies count as one; this version written 684 h after the record first saw the story; the editor kept it as written.
- Publishers
- 113
- Source articles
- 375
- Given to the writer
- 8, 7 with the article's own text
- Independent newsrooms
- 8
- This version written
- 684 h after the record first saw the story
- Second model (editor)
- kept as written
- Publication gate
- passed
- Human review
- none
WHAT THE EDITOR DID
The second model checked the writer's draft against the same sources and published it as written.
Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →